Related Experiment Videos

Clinical utility of the continuous glucose monitoring system

¹Atlanta Diabetes Associates, Georgia, USA. bbode001@aol.com

Diabetes Technology & Therapeutics

|July 27, 2001

Abstract

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Mealtime fast-acting insulin aspart versus insulin aspart for controlling postprandial hyperglycaemia in people with insulin-resistant Type 2 diabetes.

Diabetic medicine : a journal of the British Diabetic Association·2018

Safety and efficacy of insulin degludec/liraglutide (IDegLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin-naïve people with Type 2 diabetes: the DUAL IV trial.

Diabetic medicine : a journal of the British Diabetic Association·2016

One-year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26-week extension to a 26-week main trial.

Diabetes, obesity & metabolism·2015

Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metformin.

Diabetes, obesity & metabolism·2014

Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN(®) Basal-Bolus Type 1): 2-year results of a randomized clinical trial.

Diabetic medicine : a journal of the British Diabetic Association·2013

Continuous glucose monitoring in 2010.

International journal of clinical practice. Supplement·2011

See all related articles